Galectin Therapeutics Inc.

Healthcare

NASDAQ:GALT · NASDAQ Capital Market

Market Cap $156.74M Beta 0.49 P/E (TTM) -6.7

$2.67 +2.30%

+$0.06 today

52W Low $1.33High $7.13

Vol 0.28M · Avg 0.33M

EPS (TTM)-$0.40

Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+94.89%

Period High

$6.51

Period Low

$1.37

Latest

$2.67

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Alpha Tau Medical Ltd.

NASDAQ:DRTS

$889.71M

LB Pharmaceuticals Inc Common Stock

NASDAQ:LBRX

$814.99M

Design Therapeutics, Inc.

NASDAQ:DSGN

$685.15M

Aura Biosciences, Inc.

NASDAQ:AURA

$411.52M

DiaMedica Therapeutics Inc.

NASDAQ:DMAC

$304.44M

Rocket Pharmaceuticals, Inc.

NASDAQ:RCKT

$300.28M

I-Mab

IMAB

$235.66M

Altimmune, Inc.

NASDAQ:ALT

$230.35M

Quantum-Si incorporated

NASDAQ:QSI

$187.28M

enGene Holdings Inc.

NASDAQ:ENGN

$82.94M

What is the latest GALT filing?

The latest filing shown is 4 dated May 28, 2026.

How many recent filings does GALT have?

Intrinsic Alpha currently shows 20 recent filings for GALT.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.